# A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

> **NCT05357755** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 90 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** JNJ-77242113
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05357755
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-13
- **Primary completion:** 2023-03-23
- **Final completion:** 2023-04-10
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357755, "A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05357755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*